热门资讯> 正文
Innate Pharma报告第一季度业绩
2025-05-13 14:57
- Innate Pharma press release (NASDAQ:IPHA): Q1 revenue amounted to €1.2 million vs €6.6 million for the same period in 2024.
- Revenue from collaboration and licensing agreements mainly resulted from the partial or entire recognition of the proceeds received pursuant to the agreements with AstraZeneca and Sanofi.
- Cash position of €72.5 million as of March 31, 2025, excluding the €15 million received from Sanofi, with a cash horizon to mid-2026.
- Innate Pharma (IPHA) will propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a board of directors structure with a Chief Executive Officer.
- This transformation is part of the company’s strategic plan to simplify and align its governance with international standards.
More on Innate Pharma
- Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript
- Innate Pharma S.A. 2024 Q4 - Results - Earnings Call Presentation
- Innate Pharma: Moving Into The Padcev Space
- Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments
- Seeking Alpha’s Quant Rating on Innate Pharma
推荐文章
一周IPO丨中慧生物暗盘飙涨162%，中签一手赚超4000港元；“减肥药概念”银诺医药招股中
一周财经日历丨重磅财报周！腾讯京东季报轮番登场；美国7月CPI/PPI携手“恐怖数据”来袭
机器人投资风口来袭！世界级盛会催化下，哪些机会不容错过？
美股机会日报丨降息预期骤变！小摩称美联储年内或降息三次；SoundHound飙涨超27%
摩根大通预计美联储将在9月会议上降息25基点，接下来还会连续三次降息
英特尔首席执行官陈立武发文：关于过往职务信息有很多错误 董事会全力支持公司转型工作
美国养老金投资或迎巨变，特朗普颁令为401(k)纳入加密货币等资产铺路
外盘头条：OpenAI发布最强GPT-5；特朗普颁令允许养老金投资另类资产
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
